Literature DB >> 17329334

Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Adam MacNeil1, Abdoulaye Dieng Sarr, Jean-Louis Sankalé, Seema Thakore Meloni, Souleymane Mboup, Phyllis Kanki.   

Abstract

Studies have shown that human immunodeficiency virus type 2 (HIV-2) is less pathogenic than HIV-1, with a lower rate of disease progression. Similarly, plasma viral loads are lower in HIV-2 infection, suggesting that HIV-2 replication is restricted in vivo in comparison to that of HIV-1. However, to date, in vivo studies characterizing replication intermediates in the viral life cycle of HIV-2 have been limited. In order to test the hypothesis that HIV-2 has a lower replication rate in vivo than HIV-1 does, we quantified total viral DNA, integrated proviral DNA, cell-associated viral mRNA, and plasma viral loads in peripheral blood samples from groups of therapy-naïve HIV-1-infected (n = 21) and HIV-2-infected (n = 18) individuals from Dakar, Senegal, with CD4(+) T-cell counts of >200/microl. Consistent with our previous findings, total viral DNA loads were similar between HIV-1 and HIV-2 and plasma viral loads were higher among HIV-1-infected individuals. Proportions of DNA in the integrated form were also similar between these viruses. In contrast, levels of viral mRNA were lower in HIV-2 infection. Our study indicates that HIV-2 is able to establish a stable, integrated proviral infection in vivo, but that accumulation of viral mRNA is attenuated in HIV-2 infection relative to that in HIV-1 infection. The differences in viral mRNA are consistent with the differences in plasma viral loads between HIV-1 and HIV-2 and suggest that lower plasma viral loads, and possibly the attenuated pathogenesis of HIV-2, can be explained by lower rates of viral replication in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329334      PMCID: PMC1900238          DOI: 10.1128/JVI.02625-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.

Authors:  S Calcaterra; G Cappiello; A Di Caro; A R Garbuglia; A Benedetto
Journal:  J Infect       Date:  2001-11       Impact factor: 6.072

2.  Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo.

Authors:  S J Popper; A D Sarr; A Guèye-Ndiaye; S Mboup; M E Essex; P J Kanki
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.

Authors:  Michael Schindler; Jan Münch; Olaf Kutsch; Hui Li; Mario L Santiago; Frederic Bibollet-Ruche; Michaela C Müller-Trutwin; Francis J Novembre; Martine Peeters; Valerie Courgnaud; Elizabeth Bailes; Pierre Roques; Donald L Sodora; Guido Silvestri; Paul M Sharp; Beatrice H Hahn; Frank Kirchhoff
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

4.  Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

Authors:  J M Arduino; M A Fischl; K Stanley; A C Collier; D Spiegelman
Journal:  AIDS Res Hum Retroviruses       Date:  2001-08-10       Impact factor: 2.205

5.  Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Authors:  S J Popper; A D Sarr; K U Travers; A Guèye-Ndiaye; S Mboup; M E Essex; P J Kanki
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

6.  Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1.

Authors:  B Schramm; M L Penn; E H Palacios; R M Grant; F Kirchhoff; M A Goldsmith
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Long-term intrapatient viral evolution during HIV-2 infection.

Authors:  Adam MacNeil; Jean-Louis Sankale; Seema Thakore Meloni; Abdoulaye Dieng Sarr; Souleymane Mboup; Phyllis Kanki
Journal:  J Infect Dis       Date:  2007-01-18       Impact factor: 5.226

8.  Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Papa Salif Sow; Stephen E Hawes; Ibra Ndoye; Mary Redman; Awa M Coll-Seck; Mame A Faye-Niang; Aissatou Diop; Jane M Kuypers; Cathy W Critchlow; Richard Respess; James I Mullins; Nancy B Kiviat
Journal:  J Infect Dis       Date:  2002-03-19       Impact factor: 5.226

9.  Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

Authors:  Shaun K Rodriguez; Abdoulaye Dieng Sarr; Adam MacNeil; Seema Thakore-Meloni; Aissatou Gueye-Ndiaye; Ibrahima Traoré; Mamadou C Dia; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

10.  Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.

Authors:  S Andersson; H Norrgren; Z da Silva; A Biague; S Bamba; S Kwok; C Christopherson; G Biberfeld; J Albert
Journal:  Arch Intern Med       Date:  2000-11-27
View more
  44 in total

1.  HIV-2 Depletes CD4 T Cells through Pyroptosis despite Vpx-Dependent Degradation of SAMHD1.

Authors:  Xiaoyu Luo; Eytan Herzig; Gilad Doitsh; Zachary W Grimmett; Isa Muñoz-Arias; Warner C Greene
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

2.  Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Authors:  Geoffrey Férir; Dana Huskens; Kenneth E Palmer; Daniel M Boudreaux; Michael D Swanson; David M Markovitz; Jan Balzarini; Dominique Schols
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

3.  First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration.

Authors:  Julia Drylewicz; Serge Eholie; Moussa Maiga; Djimon Marcel Zannou; Papa Salif Sow; Didier K Ekouevi; Kevin Peterson; Emmanuel Bissagnene; François Dabis; Rodolphe Thiébaut
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 4.  Update on human immunodeficiency virus (HIV)-2 infection.

Authors:  Omobolaji T Campbell-Yesufu; Rajesh T Gandhi
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

5.  Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.

Authors:  Boris K Tchounga; Bo L Hønge; Serge P Eholie; Patrick A Coffie; Sanne Jespersen; Christian Wejse; François Dabis; Gottlieb S Geoffrey; Didier K Ekouevi
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

6.  Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated.

Authors:  Suzanne D G Kijewski; Hisashi Akiyama; Amin Feizpour; Caitlin M Miller; Nora-Guadalupe P Ramirez; Björn M Reinhard; Suryaram Gummuluru
Journal:  Virology       Date:  2016-08-11       Impact factor: 3.616

7.  Differences in proviral DNA load between HIV-1-infected and HIV-2-infected patients.

Authors:  Geoffrey S Gottlieb; Stephen E Hawes; Nancy B Kiviat; Papa Salif Sow
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

8.  Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses.

Authors:  Jan Münch; Devi Rajan; Michael Schindler; Anke Specht; Elke Rücker; Francis J Novembre; Eric Nerrienet; Michaela C Müller-Trutwin; Martine Peeters; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

10.  Conservation of Nef function across highly diverse lineages of SIVsmm.

Authors:  Jan Schmökel; Hui Li; Elizabeth Bailes; Michael Schindler; Guido Silvestri; Beatrice H Hahn; Cristian Apetrei; Frank Kirchhoff
Journal:  Retrovirology       Date:  2009-04-09       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.